Cover Image
市場調查報告書

全球藥物安全檢測市場預測:主要國家,主要企業,趨勢

Global Pharmacovigilance Market Forecast 2018-2028: US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends

出版商 Visiongain Ltd 商品編碼 224395
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球藥物安全檢測市場預測:主要國家,主要企業,趨勢 Global Pharmacovigilance Market Forecast 2018-2028: US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends
出版日期: 2017年12月21日 內容資訊: 英文 150 Pages
簡介

全球藥物安全檢測 (醫藥品安全性監視) 市場預測在2023年將達到115億美元。

本報告提供全球藥物安全檢測市場相關調查分析,提供研究開發費的預測,收益預測 (各區各國) 、SWOT·STEP分析,促進因素·阻礙因素,主要企業的簡介等系統性資訊。

第1章 報告概要

第2章 藥物安全檢測的簡介

  • 藥物有害反應
  • 現象
  • 安全性信號和其意義,指定方法
  • 藥物安全檢測的歷史性預測
  • 臨床實驗的醫藥品安全性監測
  • 階段IV:上市後的調查
  • 製藥產業上藥物安全檢測
  • 主要的製藥企業的藥物安全檢測實例

第3章 藥物安全檢測:全球市場

  • 由於WHO的國際醫藥品監測計劃
  • 研究開發的藥物安全檢測:預測
  • 藥物安全檢測市場:促進因素·阻礙因素

第4章 主要國家·各地區市場

  • 全球藥物安全檢測市場各地區明細
  • 全球藥物安全檢測市場:各地區預測
  • 美國
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 日本
  • 金磚四國
  • 中國
  • 巴西
  • 俄羅斯
  • 印度
  • 韓國

第5章 藥物安全檢測主要企業

  • Accenture PLC
  • Cognizant Technology Solutions Corporation
  • Tata Consultancy Services
  • Capgemini SE
  • Tech Mahindra Limited
  • Infosys Limited
  • WIPRO LIMITED
  • Oracle Corporation
  • Bristol-Myers Squibb
  • HCL Technologies Ltd.
  • Olympus Corporation

第6章 藥物安全檢測市場定性分析

第7章 結論

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0272

The global pharmacovigilance market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The pharmacovigilance market is estimated to reach $ 11.5bn in 2023.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 150-page report you will receive 47 tables and 61 figures- all unavailable elsewhere.

The 150-page report provides clear detailed insight into the global pharmacovigilance market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical R&D Spending forecasts from 2017-2028
  • Global Pharmacovigilance market forecasts from 2017-2028

This report provides individual revenue forecasts to 2027 for these regional and national markets:

  • US
  • Japan
  • EU: Germany, France, the UK, Italy, Spain, Others
  • BRIC: Brazil, Russia, India, China
  • South Korea
  • Others

This report provides a SWOT and STEP Analysis of the pharmacovigilance market. This report also discusses the Drivers and Restraints of the pharmacovigilance market.

Our study discusses the selected leading companies that are the major players in the pharmacovigilance market:

  • Accenture PLC
  • Cognizant Technology Solutions Corporation
  • Tata Consultancy Services (TCS)
  • Capgemini SE
  • Tech Mahindra Limited
  • Infosys Limited (Infosys)
  • Wipro Limited (Wipro)
  • Oracle Corporation (Oracle)
  • Bristol-Myers Squibb Company
  • HCL Technologies Ltd.
  • Olympus Corporation

Moreover, this report discusses the following:

  • Reporting systems for adverse drug reactions (ADRs) - their present and future, including data on reported and recorded events by year and region
  • Safety monitoring using reporting from social media
  • Improvements in data collection and communication leading to more-flexible drug approval processes - changing routes of marketing authorization
  • Policies of national and international bodies, and regulators' roles in present and future pharmacovigilance plans
  • Collaboration between the FDA and EMA, and application of pharmacogenomics and biomarkers
  • Use of electronic health record (EHR) systems - a live model for drug safety, applying information systems.

Visiongain's study is intended for anyone requiring commercial analyses for the global pharmacovigilance market. You find data, trends and predictions.

Buy our report today Global Pharmacovigilance Market Forecast 2018-2028: US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction to This New Study
  • 1.2. Why You Should Read This Report
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Who is This Report For?
  • 1.5. Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Introduction to Pharmacovigilance

  • 2.1. Adverse Drug Reactions
    • 2.1.1. ADRs are Not Side Effects
    • 2.1.2. Terminology in the US and EU
  • 2.2. Never Events
  • 2.3. Safety Signals, What They Mean and How to Identify Them
  • 2.4. Pharmacovigilance, a Historical Perspective
    • 2.4.1. Thalidomide
    • 2.4.2. Eraldin
    • 2.4.3. Vioxx
    • 2.4.4. Avandia
  • 2.5. Drug Safety Monitoring in Clinical Trials
    • 2.5.1. Phase I Clinical Trials
    • 2.5.2. Phase II Clinical Trials
    • 2.5.3. Phase III Clinical Trials
      • 2.5.3.1. Limitations of Phase I-III Trials
  • 2.6. Phase IV - Post-Marketing Studies
  • 2.7. Pharmacovigilance in the Pharmaceutical Industry
  • 2.8. The Pharmacovigilance Practices of the Leading Pharmaceutical Companies
    • 2.8.1. Pfizer
    • 2.8.2. Johnson & Johnson
    • 2.8.3. GlaxoSmithKline
    • 2.8.4. Sanofi
    • 2.8.5. Novartis
    • 2.8.6. AstraZeneca
    • 2.8.7. Roche
    • 2.8.8. Abbott Laboratories
    • 2.8.9. Eli Lilly
    • 2.8.10. Bristol-Myers Squibb

3. Pharmacovigilance: World Market 2018-2028

  • 3.1. The WHO Programme for International Drug Monitoring
    • 3.1.1. Data Collection at the Uppsala Monitoring Centre
    • 3.1.2. VigiBase - The Global Drug Safety Repository
  • 3.2. Pharmacovigilance in Research and Development: Forecast 2018-2028
  • 3.3. Pharmacovigilance Market: Drivers and Restraints 2018-2028
    • 3.3.1. Volume of ADRs Set to Rise
    • 3.3.2. Reduced Pre-Market Safety Data - Focus Shifts to Post-Approval Monitoring
    • 3.3.3. New EU Regulations Will Demand a Revamp of Entire Pharmacovigilance Protocols
    • 3.3.4. Active Drug Safety Monitoring Set to Increase
    • 3.3.5. Lack of Harmonisation Leads to Cross Border Difficulties
    • 3.3.6. Transparency is Crucial in the Future of Pharmacovigilance
    • 3.3.7. Direct Consumer Reports Lack Quality to Detect Causal Safety Signals
    • 3.3.8. Merged Companies Spend Less on Pharmacovigilance

4. Leading National and Regional Markets, 2018-2028

  • 4.1. Regional Breakdown of the World Pharmacovigilance Market, 2017
  • 4.2. World Pharmacovigilance Market: Regional Forecast 2018-2028
    • 4.2.1. How Will Regional Market Shares Change to Between 2018 and 2028?
  • 4.3. The US Pharmacovigilance Market, 2018-2028
    • 4.3.1. Criticism of the FDA
    • 4.3.2. Periodic and Spontaneous Safety Reports
    • 4.3.3. ADR Metrics for the US Market
    • 4.3.4. US Market Forecast, 2018-2028
  • 4.4. The European Pharmacovigilance Market, 2018-2028
    • 4.4.1. New EU Regulations Making the Biggest Impact for Twenty Years
    • 4.4.2. Quality at the Heart of Safety Monitoring
    • 4.4.3. Pharmacovigilance System Master File - Added Complexity in the Short Term
    • 4.4.4. ADR Reporting and Safety Signal Detection
    • 4.4.5. EU Market Forecast, 2018-2028
    • 4.4.6. ADR Metrics for the European Union, 2012
  • 4.5. The German Pharmacovigilance Market, 2018-2028
    • 4.5.1. German Market Forecast, 2018-2028
  • 4.6. The French Pharmacovigilance Market, 2018-2028
    • 4.6.1. French Market Forecast, 2018-2028
  • 4.7. The UK Pharmacovigilance Market 2018-2028
    • 4.7.1. UK Market Forecast, 2018-2028
  • 4.8. The Italian Pharmacovigilance Market, 2018-2028
    • 4.8.1. Italian Market Forecast, 2018-2028
  • 4.9. The Spanish Pharmacovigilance Market 2018-2028
    • 4.9.1. Spanish Market Forecast, 2018-2028
  • 4.10. Japanese Pharmacovigilance Market 2018-2028
    • 4.10.1. Early Stage Drug Monitoring
    • 4.10.2. Expedited and Periodic Safety Reports
    • 4.10.3. Japanese Market Forecast, 2018-2028
  • 4.11. Pharmacovigilance in the BRIC Nations, 2018-2028
  • 4.12. The Chinese Pharmacovigilance Market, 2018-2028
    • 4.12.1. ADR Metrics for the Chinese Market 2003-2012
    • 4.12.2. Chinese Market Forecast, 2018-2028
  • 4.13. The Brazilian Pharmacovigilance Market, 2018-2028
    • 4.13.1. Brazilian Market Forecast, 2018-2028
  • 4.14. The Russian Pharmacovigilance Market, 2018-2028
    • 4.14.1. Russian Market Forecast, 2018-2028
  • 4.15. The Indian Pharmacovigilance Market, 2018-2028
    • 4.15.1. ADR Metrics for Indian Market
    • 4.15.2. Indian Market Forecast 2018-2028
  • 4.16. The South Korean Pharmacovigilance Market, 2018-2028
    • 4.16.1. ADR Metrics for South Korea
    • 4.16.2. South Korean Market Forecast, 2018-2028

5. Leading Pharmacovigilance Companies, 2018

  • 5.1. Accenture PLC
    • 5.1.1. Accenture PLC: Company Overview
    • 5.1.2. Accenture PLC: Product Portfolio
  • 5.2. Cognizant Technology Solutions Corporation
    • 5.2.1. Cognizant Technology Solutions Corporation: Company Overview
    • 5.2.2. Cognizant Technology Solutions Corporation: Product Portfolio
  • 5.3. Tata Consultancy Services
    • 5.3.1. Tata Consultancy Services: Company Overview
  • 5.4. Capgemini SE
    • 5.4.1. Capgemini SE: Company Overview
    • 5.4.2. Capgemini SE: Product Portfolio
  • 5.5. Tech Mahindra Limited
    • 5.5.1. Tech Mahindra Limited: Company Overview
    • 5.5.2. Tech Mahindra Limited: Recent Developments
  • 5.6. Infosys Limited
    • 5.6.1. Infosys Limited: Company Overview
    • 5.6.2. Infosys Limited: Product Portfolio
  • 5.7. WIPRO LIMITED
    • 5.7.1. Wipro Limited: Company Overview
    • 5.7.2. Wipro Limited: Product Portfolio
  • 5.8. Oracle Corporation
    • 5.8.1. Oracle Corporation: Company Overview
    • 5.8.2. Oracle Corporation: Product Portfolio
    • 5.8.3. Oracle Corporation: Recent Developments
  • 5.9. Bristol-Myers Squibb
    • 5.9.1. Bristol-Myers Squibb: Company Overview
    • 5.9.2. Bristol-Myers Squibb: Product Portfolio
  • 5.10. HCL Technologies Ltd.
    • 5.10.1. HCL Technologies Ltd.: Company Overview
    • 5.10.2. HCL Technologies Ltd.: Product Portfolio
  • 5.11. Olympus Corporation
    • 5.11.1. Olympus Corporation: Company Overview
    • 5.11.2. Olympus Corporation: Product Portfolio

6. Qualitative Analysis of the Pharmacovigilance Market 2018-2028

  • 6.1. SWOT Analysis of the Pharmacovigilance Market
  • 6.2. STEP Analysis of the Pharmacovigilance Market
  • 6.3. Social Forces
  • 6.4. Technological Forces
  • 6.5. Economic Forces
  • 6.6. Political Forces
  • 6.7. Increased Focus on Pharmacovigilance in the Emerging Markets
  • 6.8. Increasingly Complex Nature of Pharmaceutical Vigilance
  • 6.9. Harmonization of International Regulations Can Lead to Cost Reductions
  • 6.10. The Effect of the Internet and Social Media on ADR Reporting
  • 6.11. Collaboration between the FDA and EMA
  • 6.12. The Challenge of Obtaining High-Quality ADR Information
  • 6.13. Linking Pharmacovigilance to Genomics and Biomarkers
  • 6.14. Generics, Globalisation and Drug Safety

7. Conclusions

  • 7.1. International Collaboration Will Increase
  • 7.2. Pharmacogenomics Will Become Important in Drug Approval and Safety Analysis
  • 7.3. Drug Safety Monitoring Will Become Active
  • 7.4. Social Media Will Become a Pharmacovigilance Tool

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1: Pharmacovigilance Terminology in the EU and US, 2017
  • Table 2.2: Sample Size Required to Detect ADRs Based on Incidence, 2017
  • Table 2.3: Number of Phase IV Clinical Trials by Registration Date, 2004-2016
  • Table 3.1: Full Members of the WHO Program for Drug Safety Monitoring, 2017
  • Table 3.2: Global Pharmaceutical R&D Spending Forecast: Global Spending on R&D ($bn), Annual Growth (%), CAGR (%), 2017-2028
  • Table 4.1: Spending on Pharmacovigilance in National and Regional Markets: Market Size ($bn), 2017
  • Table 4.2: Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.3: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Shares (%), 2018-2028
  • Table 4.4: Forecast Spending on Pharmacovigilance in the US: Spending ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.5: Forecast Spending on Pharmacovigilance in the European Union: National Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2018-2028
  • Table 4.6: Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2017
  • Table 4.7: Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.8: Forecast Spending on Pharmacovigilance in France: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.9: Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.10: Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.11: Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.12: Drug Re-examination Schedule in Japan, 2017
  • Table 4.13: Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.14: Forecast Spending on Pharmacovigilance in the BRIC Nations: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2028
  • Table 4.15: Forecast Spending on Pharmacovigilance in China: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.16: Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.17: Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.18: Forecast Spending on Pharmacovigilance in India: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 4.19: Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2028
  • Table 5.1: Accenture PLC: Company Overview
  • Table 5.2: Accenture PLC: Product Portfolio
  • Table 5.3: Cognizant Technology Solutions Corporation: Company Overview
  • Table 5.4: Cognizant Technology Solutions Corporation: Product Portfolio
  • Table 5.5: Tata Consultancy Services: Company Overview
  • Table 5.6: Capgemini SE: Company Overview
  • Table 5.7: Capgemini SE: Product Portfolio
  • Table 5.8: Tech Mahindra Limited: Company Overview
  • Table 5.9: Tech Mahindra Limited: Recent Developments
  • Table 5.10: Infosys Limited: Company Overview
  • Table 5.11: Infosys Limited: Product Portfolio
  • Table 5.12: Wipro Limited: Company Overview
  • Table 5.13: Wipro Limited: Product Portfolio
  • Table 5.14: Oracle Corporation: Company Overview
  • Table 5.15: Oracle Corporation: Product Portfolio
  • Table 5.16: Oracle Corporation: Recent Developments
  • Table 5.17: Bristol-Myers Squibb: Company Overview
  • Table 5.18: Bristol-Myers Squibb: Product Portfolio
  • Table 5.19: HCL Technologies Ltd.: Company Overview
  • Table 5.20: HCL Technologies Ltd.: Product Portfolio
  • Table 5.21: Olympus corporation: Company Overview
  • Table 5.22: Olympus corporation: Product Portfolio
  • Table 6.1: Social, Technological, Economic, and Political Factors (STEP) Affecting Pharmacovigilance, 2018

List of Figures

  • Figure 2.1: Lifecycle of Adverse Events for Vioxx, 1999-2004
  • Figure 2.2: Lifecycle of Adverse Events for Avandia, 1999-2010
  • Figure 2.3: Number of Phase IV Clinical Trials by Registration Date, 2004-2016
  • Figure 3.1: Country of Origin of ICSRs on UMC VigiBase: National Percentage of Cumulative ISCR Total (%), 2017
  • Figure 3.2: Per Capita ISCRs Submitted to VigiBase: Number ICSRs Submitted Per Million Inhabitants Per Year, Yearly Average, 2017
  • Figure 3.3: Global Pharmaceutical R&D Spending Forecast: Spending ($bn), AGR (%), 2018-2028
  • Figure 3.4: Pharmacovigilance Market: Drivers and Restraints, 2018-2028
  • Figure 4.1: Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2017
  • Figure 4.2: Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), 2018-2028
  • Figure 4.3: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2023
  • Figure 4.4: Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2028
  • Figure 4.5: Forecast Spending on Pharmacovigilance in the US: Market Size ($bn), 2018-2028
  • Figure 4.6: Forecast Spending on Pharmacovigilance in European Union (EU5): National Market Sizes ($bn), 2018-2028
  • Figure 4.7: Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2017
  • Figure 4.8: Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), 2018-2028
  • Figure 4.9: Forecast Spending on Pharmacovigilance in France: Market Size ($bn), 2018-2028
  • Figure 4.10: Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), 2018-2028
  • Figure 4.11: Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), 2018-2028
  • Figure 4.12: Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), 2018-2028
  • Figure 4.13: Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), 2018-2028
  • Figure 4.14: Forecast Spending on Pharmacovigilance in BRIC Nations: National Marker Sizes ($bn), 2018-2028
  • Figure 4.15: Forecast Spending on Pharmacovigilance in China: Market Size ($bn), 2018-2028
  • Figure 4.16: Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), 2018-2028
  • Figure 4.17: Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), 2018-2028
  • Figure 4.18: Forecast Spending on Pharmacovigilance in India: Market Size ($bn), 2018-2028
  • Figure 4.19: Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), 2018-2028
  • Figure 5.1: Accenture PLC, Revenue, ($million), 2012-2016
  • Figure 5.2: Accenture PLC, Product Segments Share (%), 2016
  • Figure 5.3: Accenture PLC, Geography Share (%), 2016
  • Figure 5.4: Cognizant Technology Solutions Corporation, Revenue, ($million), 2012-2016
  • Figure 5.5: Cognizant Technology Solutions Corporation, Product Segments Share (%), 2016
  • Figure 5.6: Cognizant Technology Solutions Corporation, Geographical Presence Share (%), 2016
  • Figure 5.7: Tata Consultancy Services, Revenue, ($million), 2013-2017
  • Figure 5.8: Tata Consultancy Services, Product Segments Share (%), 2017
  • Figure 5.9: Tata Consultancy Services, Geographical Presence Share (%), 2017
  • Figure 5.10: Capgemini SE, Revenue, ($million), 2012-2016
  • Figure 5.11: Capgemini SE, Product Segments Share (%), 2016
  • Figure 5.12: Capgemini SE, Geographical Presence Share (%), 2016
  • Figure 5.13: Tech Mahindra Limited, Revenue, ($million), 2013-2017
  • Figure 5.14: Tech Mahindra Limited, Product Segments Share (%), 2017
  • Figure 5.15: Tech Mahindra Limited, Geographical Presence Share (%), 2017
  • Figure 5.16: Infosys Limited, Revenue, ($million), 2013-2017
  • Figure 5.17: Infosys Limited, Product Segments Share (%), 2017
  • Figure 5.18: Infosys Limited, Geographical Presence Share (%), 2017
  • Figure 5.19: Wipro Limited, Revenue, ($million), 2013-2017
  • Figure 5.20: Wipro Limited, Product Segments Share (%), 2016
  • Figure 5.21: Wipro Limited, Geographical Presence Share (%), 2016
  • Figure 5.22: Oracle Corporation, Revenue, ($million), 2013-2017
  • Figure 5.23: Oracle Corporation, Product Segments Share (%), 2017
  • Figure 5.24: Oracle Corporation, Geographical Presence Share (%), 2017
  • Figure 5.25: Bristol-Myers Squibb, Revenue, ($million), 2012-2016
  • Figure 5.26: Bristol-Myers Squibb, Product Segments Share (%), 2016
  • Figure 5.27: Bristol-Myers Squibb, Geographical Presence Share (%), 2016
  • Figure 5.28: HCL Technologies Ltd., Revenue, ($million), 2013-2017
  • Figure 5.29: HCL Technologies Ltd., Product Segments Share (%), 2017
  • Figure 5.30: HCL Technologies Ltd., Geographical Presence Share (%), 2017
  • Figure 5.31: Olympus corporation, Revenue, ($million), 2013-2017
  • Figure 5.32: Olympus corporation, Product Segments Share (%), 2017
  • Figure 5.33: Olympus corporation, Geographical Presence Share (%), 2017
  • Figure 6.1: Strengths and Weaknesses Within Pharmacovigilance, 2017
  • Figure 6.2: Opportunities and Threats Within Pharmacovigilance, 2017

Companies Listed

  • Abbott Laboratories
  • Accenture
  • Accovion
  • Actavis
  • Aprova
  • Aptiv Solutions
  • Aris Global
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Capgemini
  • Cognizant Technology Solutions
  • Covance
  • Crossoak Pharma
  • Crown Consultants
  • CSO Pharma Consulting
  • DADA Consultancy
  • Dose Spot
  • Drug Safety Alliance
  • Dun & Bradstreet
  • Eli Lilly
  • Epidemico
  • Facebook
  • First Databank
  • Foresight Group International
  • Forest Laboratories
  • GB Pharma
  • Geneix
  • GlaxoSmithKline (GSK)
  • Handle My Health
  • Harten Group
  • HCL Technologies
  • ICON
  • iGATE Corporation
  • Illumina
  • iMED Global
  • Imperial Chemical Industries
  • INC Research
  • Infosys
  • inVentiv Health
  • IPM Safety Services
  • Johnson & Johnson
  • Kinapse
  • Lindeq
  • Mahindra Satyam
  • MedImmune
  • Merck & Co.
  • Merck Serono
  • NDA Group
  • Nhumi Technologies
  • Novartis
  • November Research Group
  • Novo Nordisk
  • Optum
  • Oracle
  • Orbis Clinical
  • ParagonRX
  • Parexel
  • PatientsLikeMe
  • Patni Computer Systems
  • Paul Ehrlich Institute
  • Pfizer
  • PharSafer
  • PPD
  • PRA International
  • Primevigilance
  • Quanticate
  • Quantum Solutions India
  • Quintiles Transnational
  • Ranbaxy
  • Roche
  • Sanofi
  • Sciformix
  • Servier
  • SGS Life Sciences
  • Sun Pharmaceuticals
  • Symogen
  • Synowledge
  • TAKE Solutions
  • Tata Consultancy Services
  • Tech Mahindra
  • Twitter
  • UDG Healthcare
  • uMotif
  • Unified Health System
  • United Biosource Company
  • Uppsala Monitoring Centre (UMC))
  • Warner Chilcott
  • Watson
  • Wipro Limited
  • Wockhardt
  • Xendo

List of Organizations Mentioned in the Report:

  • Agence française de sécurité sanitaire des produits de santé
  • Agencia Española de Medicamentos y Productos Sanitarios
  • Agenzia Italiana del Farmaco (AIFA)
  • Brazilian Health Surveillance Agency (ANVISA)
  • Center for Biologics Evaluation and Research
  • Center for Drug Evaluation and Research
  • Central Drugs Standard Control Organization
  • China Food and Drug Agency
  • China Food and Drug Agency (CFDA)
  • Chinese Ministry of Health
  • Commission on Human Medicines
  • Committee for Medicinal Products for Human Use
  • Committee on the Safety of Medicine
  • Contergan Foundation
  • Danish Medicines Agency
  • Dutch Medicines Evaluation Board
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • European Medicines Evaluation Agency (EMEA)
  • European Union (EU)
  • Federal Association of Thalidomide Victims
  • Federal Centre for Monitoring Drug Safety
  • Federal Institute for Drugs and Medical Devices
  • Federal Service on Surveillance in Healthcare and Social Development (Roszdravnadzor, Russia)
  • Food and Drug Administration (US FDA)
  • Indian Pharmacopoeia Commission
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Korea Food and Drug Administration
  • Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
  • Ministero della Salute
  • Ministry of Food and Drug Safety (MFDS, Korea)
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • National Agency for Safety of Medicine and Health Products
  • National Patient Safety Agency
  • Norwegian Medicines Agency
  • Pharmaceutical and Medical Devices Agency (PMDA, Japan)
  • Pharmacovigilance Risk Assessment Committee
  • Serious Adverse Event Consortium (SAEC)
  • Shenyang Pharmaceutical University
  • State Food and Drug Agency
  • World Bank
  • World Health Organization (WHO)
Back to Top